NCT05977868

Comparing Oral Versus Parenteral Antimicrobial Therapy

Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 94 (actual)
• Sponsor: West Virginia University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator initiated multisite pragmatic randomized controlled trial designed to demonstrate equivalent effectiveness with improved safety of early transition from intravenous (IV) antimicrobial therapy to complex outpatient oral antimicrobial therapy (COpAT) across various infectious diseases (endovascular, bone and joint, skin and soft tissue, pulmonary, gastrointestinal, and genitourinary infections). All patients referred for outpatient parenteral antimicrobial therapy (OPAT) will be evaluated by the research team with respect to inclusion/exclusion criteria. If determined eligible for enrollment, patients will be approached by a study investigator who will present the COPAT Trial. Once informed consent is obtained, patients will be randomized 2:1 using computer software into experimental or control (standard of care) group, respectively: Experimental: COpAT only on hospital discharge; Control: Conventional OPAT, OPAT transitioned to COpAT later in outpatient setting, or long-acting parenteral lipoglycopeptides. Both groups will be followed by an ID physician on the research team with in-person or telemedicine ID Clinic standard of care visits at 2, 6, and 12 weeks after hospital discharge. At the 6-week ID Clinic follow-up, patients will be asked to complete a patient satisfaction survey. The following 2 primary outcomes will be assessed: cure at 3 months using clinical (resolution of infection) and laboratory (improvement in inflammatory markers) parameters and adverse events related to antimicrobial therapy/vascular access complication or readmission at 3 months. The following secondary outcome will be assessed: patient satisfaction at 6 weeks. The experimental group is being compared to standard of care in current clinical practice. As this is a pragmatic clinical trial, patients will not undergo additional invasive testing or procedures.

Conditions

• Endovascular Infection
• Bone and Joint Infection
• Skin and Soft Tissue Infection
• Pulmonary Infection
• Gastrointestinal Infection
• Genitourinary Infection

Interventions

Type	Name	Description
DRUG	Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid	COpAT (oral antimicrobial therapy) on hospital discharge
DRUG	Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem	Standard of care (IV antimicrobial therapy) on hospital discharge

Timeline

• Start date: 2023-08-04
• Primary completion: 2025-02-14
• Completion: 2025-02-14
• First posted: 2023-08-07
• Last updated: 2025-08-26
• Results posted: 2025-08-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study